December 7 Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Amicus Therapeutics, Inc.

Glancy Prongay & Murray LLP (“GPM”) reminds investors that a class action complaint has been filed on behalf of a class of Amicus Therapeutics, Inc. (“Amicus” or the “Company”) (NASDAQ: FOLD) investors who purchased shares between September 15, 2015 and October 1, 2015, inclusive (the “Class Period”). Amicus investors have until December 7, 2015 to file a lead plaintiff motion. Investors are encouraged to contact GPM to discuss their legal rights.

On October 2, 2015, the Company disclosed that the FDA had “requested further integration of existing clinical data across studies” in connection with Amicus’s migalastat monotherapy treatment for Fabry disease, and that, “Amicus does not anticipate being in a position to submit the NDA for migalastat monotherapy in the United States by the end of this year.” On this news, the Company’s stock fell $7.36, or over 53%, to close at $6.39 on October 2, 2015, thereby injuring Amicus investors. The complaint alleges that Amicus misled investors regarding the Company’s prospects for FDA approval.

If you purchased shares of Amicus during the Class Period you may move the Court no later than December 7, 2015 to request appointment as lead plaintiff. If you purchased Amicus securities during the Class Period, or if you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151123005048/en/